Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 12;41(6):3189–3200. doi: 10.3892/or.2019.7113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Cheng et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Western blotting detects EMT-related protein expression levels after ARPC2 knockdown or overexpression. (A) MCF-7 cells were stably transfected with NC or pcDNA3.1-ARPC2, and the levels of p-Smad2 and Smad2/3 were assessed by western blotting. *P<0.05. (B) MCF-7 cells were treated with 10 ng/l SB43 or DMSO for 48 h, and the protein expression levels of EMT markers, p-Smad2 and total Smad2/3 protein were assessed by western blotting. *P<0.05. (C) Western blotting was performed to examine ARPC2, E-cadherin, and vimentin expression after 48 h of treatment with TGF-β in siCtrl and siARPC2. *P<0.05. (D) Effect of ARPC2 downregulation, analysis of the expression of ARPC2, E-cadherin, vimentin, MMP-9, MMP-3 and ZEB-1 by western blotting. *P<0.05. (E) Effect of ARPC2 overexpression. Analysis of the level of ARPC2, E-cadherin, vimentin, MMP-9, MMP-3 and ZEB-1 by western blotting. *P<0.05. (F) ARPC2 mRNA expression levels in MDA-MB-231 cells treated with different concentrations of TGF-β at 48 h and (10 ng/ml) TGF-β at different time-points. EMT, epithelial-mesenchymal transition; ARPC2, actin-related protein 2/3 complex. *P<0.05, **P<0.01.

Figure 4. — Western blotting detects EMT-related protein expression levels after ARPC2 knockdown or overexpression. (A) MCF-7 cells were stably transfected with NC or pcDNA3.1-ARPC2, and the levels of p-Smad2 and Smad2/3 were assessed by western blotting. *P<0.05. (B) MCF-7 cells were treated with 10 ng/l SB43 or DMSO for 48 h, and the protein expression levels of EMT markers, p-Smad2 and total Smad2/3 protein were assessed by western blotting. *P<0.05. (C) Western blotting was performed to examine ARPC2, E-cadherin, and vimentin expression after 48 h of treatment with TGF-β in siCtrl and siARPC2. *P<0.05. (D) Effect of ARPC2 downregulation, analysis of the expression of ARPC2, E-cadherin, vimentin, MMP-9, MMP-3 and ZEB-1 by western blotting. *P<0.05. (E) Effect of ARPC2 overexpression. Analysis of the level of ARPC2, E-cadherin, vimentin, MMP-9, MMP-3 and ZEB-1 by western blotting. *P<0.05. (F) ARPC2 mRNA expression levels in MDA-MB-231 cells treated with different concentrations of TGF-β at 48 h and (10 ng/ml) TGF-β at different time-points. EMT, epithelial-mesenchymal transition; ARPC2, actin-related protein 2/3 complex. *P<0.05, **P<0.01.